Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H. Brannagan, Annabel K. Wang, Michael Polydefkis et al.|Journal of Neurology|2022Cited by 36
Fentanyl Buccal Tablet Compared with Immediate-Release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Cancer and Noncancer Pain: A Randomized, Double-Blind, Crossover Study Followed by a 12-Week Open-Label Phase to Evaluate Patient OutcomesLynn R. Webster, Ronghua Yang, Kieran A. Slevin et al.|Pain Medicine|2013Cited by 29
Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosisTeresa Coelho, Morie A. Gertz, Carol Whelan et al.|Journal of the Neurological Sciences|2021Cited by 0